NCT04269278

Brief Summary

Dexmedetomidine may alter whole blood coagulation. However, little is known about the dose-response relationships according to the blood concentration of dexmedetomidine. The investigators have therefore performed the present study to measure the effect of dexmedetomidine on the coagulation pathway according to the drug concentration level using a rotational thromboelastometry test.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 11, 2020

Completed
1 day until next milestone

Study Start

First participant enrolled

February 12, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 13, 2020

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2020

Completed
Last Updated

July 2, 2021

Status Verified

June 1, 2021

Enrollment Period

11 months

First QC Date

February 11, 2020

Last Update Submit

June 30, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • FIBTEM

    Fibrinolytic pathway values of rotational thromboelastometry analysis/ FIBTEM is not an acronym.

    During the rotational thromboelastometry analysis/ an average of 1 hour

Secondary Outcomes (2)

  • INTEM

    During the rotational thromboelastometry analysis/ an average of 1 hour

  • EXTEM

    During the rotational thromboelastometry analysis/ an average of 1 hour

Study Arms (4)

0 ng/ml

Blood specimen which was added 0 ul of dexmedetomidine

Drug: 0 ul of dexmedetomidine

0.5 ng/ml

Blood specimen which was added 0.25 ul of dexmedetomidine

Drug: 0.25 ul of dexmedetomidine

1.0 ng/ml

Blood specimen which was added 0.5 ul of dexmedetomidine

Drug: 0.5 ul of dexmedetomidine

1.5 ng/ml

Blood specimen which was added 0.75 ul of dexmedetomidine

Drug: 0.75 ul of dexmedetomidine

Interventions

Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using dexmedetomidine

0 ng/ml

Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.25 ul) using dexmedetomidine

0.5 ng/ml

Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.5 ul) using dexmedetomidine

1.0 ng/ml

Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.75 ul) using dexmedetomidine

1.5 ng/ml

Eligibility Criteria

Age20 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Healthy volunteers

You may qualify if:

  • Healthy volunteers
  • Age: 20 to 65 years
  • Body weight \> 50 kg
  • Volunteers who provided informed consent

You may not qualify if:

  • Hematologic disease
  • Anticoagulant medication

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 13620, South Korea

Location

Related Publications (1)

  • Shin HJ, Boo G, Na HS. Effects of dexmedetomidine on blood coagulation: an in vitro study using rotational thromboelastometry. J Anesth. 2021 Oct;35(5):633-637. doi: 10.1007/s00540-021-02969-x. Epub 2021 Jul 15.

MeSH Terms

Conditions

Blood Coagulation Disorders

Interventions

Dexmedetomidine

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Hyo-Seok Na, MD., PhD.

    Seoul National University Bundang Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

February 11, 2020

First Posted

February 13, 2020

Study Start

February 12, 2020

Primary Completion

December 30, 2020

Study Completion

December 30, 2020

Last Updated

July 2, 2021

Record last verified: 2021-06

Locations